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Animal models play a key role in the development of novel treatments
for human disease. This is particularly true for rare diseases – defined
as disorders that affect less than 1 in 2000 people in the human
population – for which, very often, there are no effective methods of
treatment. Pharmaceutical companies are increasingly focussing on
the development of therapies for the more than 7000 rare diseases.
Because the majority of these are the result of single gene disorders,
the exceptional ability to manipulate the mouse genome means that
many such studies will take place in the laboratory mouse. But how
good are the mouse models and how useful are they in assessing the
potential for translational medicine? In this Editorial, I will discuss
current difficulties in translational research as well as examples of
good laboratory practice and guidelines that are being implemented
to improve the translational potential of animal studies in the field of
neuromuscular rare diseases. This could represent a potentially
useful approach for adoption by other disease fields to achieve a
greater success rate in translational studies.
Lost in translation: improving animal experiments
Despite continuous research efforts to advance our understanding of
rare diseases and to discover potential targets for therapy, 20 years
ago there was little interest in rare diseases from pharmaceutical
companies. However, changes in the regulatory pathways, a
decrease in the space for development of blockbuster drugs (drugs
that generate annual sales of at least $1 billion), increased societal
criticism of the pharmaceutical industry, and cost models pioneered
by companies like Genzyme have made rare diseases both a
potentially profitable investment and a public relations winner. The
rare diseases space allows for the development and approval of
novel technologies and targets that could go on to have very wide
applications. For example, inhibition of myostatin, a negative
regulator of muscle mass, has the potential to not only address some
of the problems associated with a number of neuromuscular
disorders but might also be applicable to the treatment of muscle
wasting associated with bed rest for a variety of medical conditions
as well as the loss of muscle mass and function associated with
aging (Jasuja and LeBrasseur, 2014). This would indeed be a
blockbuster drug but with the proof-of-principle and initial
registration via rare diseases.
There are concerns that animal models only provide limited and
potentially misleading results that could negatively impact
subsequent human clinical trials. Indeed, there are many examples
of animal experiments that have preceded unsuccessful clinical
trials, such that critics have argued that animal experiments are
misleading or even of no value. The alternative view is that animal
experiments are informative in the majority of cases but only if we
conduct them appropriately and analyse them critically with care.
So, what are the major problems with many animal experiments to
date?
“…critics have argued that animal
experiments are misleading or even of no
value. The alternative view is that animal
experiments are informative in the
majority of cases but only if we conduct
them appropriately and analyse them
critically with care”
Firstly, and perhaps most importantly, animal experiments to
develop new therapies need to be conducted with translation in
mind. It is vital that such studies should use doses that can
realistically be applied to humans, with appropriate metabolic
scaling calculations, as opposed to dosing to a maximum effect that
might not be possible in human studies where safety is of over-
riding importance. Rodents are remarkably resilient: mice can
survive a doubling of their blood volume in 10 seconds, an event
that would be lethal to larger animals. Indeed, as a prey species,
mice show very few signs of discomfort, which might mislead
investigators into thinking that high doses of a drug have no adverse
effects. Routes of administration that are commonly used in rodents,
such as intraperitoneal injections, will not be used in humans and
may result in very different pharmacokinetics.
It is also essential that the results of treatments are evaluated in an
appropriate manner that reflects the translational relevance of the
animal model and is not potentially subject to other interpretations.
Outcome measures used in testing the effects of a potential therapy
in an animal model should be carefully considered. Examples of
these problems are given below.
In addition, it is vital that the animal experiments are conducted
using good laboratory practice and are reported in full; for example,
in compliance with the ARRIVE guidelines (Kilkenny et al., 2010).
Randomisation and blinding to treatment are absolutely essential in
order to give confidence that the analysis has been performed
without unintentional bias. Replication in another independent
laboratory is also a very important safeguard to ensure that clinical
development is not based on an erroneous set of results. If the group
developing the novel therapy is concerned about intellectual
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property (IP), this should not be a barrier: the confirmatory studies
can always be undertaken using a contract research organisation that
makes no demands on IP but merely acts on a fee-for-services basis.
Learning from animal models of neuromuscular diseases
An examination of several animal models for neuromuscular
disease might help to illustrate many of the above issues.
Duchenne muscular dystrophy (DMD) is an X-linked lethal
muscle wasting disorder characterised by repeated degeneration of
skeletal muscle, initially followed by regeneration but this fails over
time as muscles become fibrosed and fat replaces the lost muscle
(Bushby et al., 2010; Kinali et al., 2011). The disease is due to
mutations in a very large gene, the DMD gene, encoding the large
protein dystrophin, which links the internal cytoskeleton of the
muscle fibre with the extracellular matrix. The condition affects
about 1 in 5000 live male births and has a similar incidence
regardless of race or geographical location (Mah et al., 2014). The
mdx mouse is the most commonly used model of DMD and arose
from a spontaneous murineDmdmutation in a colony of C57BL/10
mice (Bulfield et al., 1984). Many of the more than 2500 papers
published using the mdx mouse have evaluated a wide range of
potential treatments, but relatively few have been translated to
successful clinical trials. Many of the studies have involved
treatment of young mdx mice, often starting at 4-6 weeks old.
However, at this age the mouse is still developing the disease,
having shown no histopathological evidence of disease until
3 weeks of age followed by a sudden onset of muscle necrosis
that eventually involves most of the skeletal muscle fibres and then
stabilises to a less florid pattern of necrosis by 8-10 weeks of age
(Grounds et al., 2008). In contrast, extensive muscle damage can be
detected in neonates with DMD and, for the foreseeable future, all
DMD patients will have established disease at the time treatment is
initiated. Thus, data from short-term treatment of mdx mice with
developing disease might not have significant translational value for
DMD patients. A second problem is that the dose reported for many
of the mdx studies is simply impossible to achieve in man without
severe side effects. A third problem is that very few of the published
manuscripts make any mention of randomisation and blinding to
avoid bias. Finally, a fourth problem is that many of the measures
used to determine the effect of treatment are assessed differently
from lab to lab, making comparison of different treatments
effectively impossible.
The muscular dystrophy community has tried to address this final
problem by publishing standard operating procedures for many of
the common methods that have been validated by a panel of experts.
This consensus approach was under the aegis of Treat-NMD, an
international consortium of clinicians and scientists dealing with
neuromuscular diseases originally established as an EU-funded
‘network of excellence’ that launched in January 2007. The standard
operating procedures can be accessed through the Treat-NMD
website (http://www.treat-nmd.eu/research/preclinical/dmd-sops/).
Even so, some of the measures can have confounding influences.
One of the often-raised criticisms of the mdx model is that, unlike
DMD patients, who lose independent ambulation by 12 years old
and without medical intervention die by 16 years old, the mice show
no easily recognisable clinical signs of muscular dystrophy and only
have a moderately shorter lifespan than wild-type mice
(Chamberlain et al., 2007). Attempts have been made to develop
whole-body tests of muscle strength and behavioural monitoring to
capture the effects of muscular dystrophy in themdxmice, and these
have been used to evaluate treatment effects. However, such tests
might be confounded by drugs that modify CNS processes because
these might change the motivational state of the mice, either
obscuring beneficial effects of treatment or giving a falsely positive
impression of these effects.
However, there are a number of assays that show the similarities
of the disease in mouse and man and that can be used to more
accurately reflect the translational potential of novel treatments.
Histopathology in the mdx mouse is similar to the early stage of
DMD, although the limb muscles do not develop the substantial
fibrosis and fatty infiltration seen in older DMD muscle. The
diaphragm is an exception because it develops a very marked
fibrosis and associated fibre loss (Stedman et al., 1991). Drugs that
decrease the progression of fibrosis in the mdx diaphragm are quite
likely to have utility in DMD. Muscle physiology in the mdxmouse
also correlates well with the human condition. Dystrophic muscle in
both mouse and man is highly vulnerable to damage as the result of
eccentric exercise (lengthening contractions), and drugs that protect
the muscle against eccentric damage are also likely to translate well.
Finally, the maximum specific twitch and tetanic forces are reduced
in dystrophic muscle and can be improved by some drug treatments
or the restoration of dystrophin (e.g. Godfrey et al., 2015). An
important point that is often overlooked is the extent to which the
therapeutic intervention in the mdx mouse restores the measure to
that of thewild-type mouse. A useful evaluation is the concept of the
recovery score developed by Jean-Marie Gillis in the context of
analysing transgenic dystrophic mice (Gillis, 2002), where the
percentage change in any measure from the mdx to the wild-type
indicates the level of the treatment effect.
Amyotrophic lateral sclerosis (ALS) is another muscle-wasting
disease but, in contrast to DMD, ALS arises from the loss of the
motoneurons innervating the muscles. Diagnosis is commonly
about the age of 50 and survival after diagnosis is generally only
2-4 years. About 10% of cases have a familial basis, whereas the
remaining 90% seem to be sporadic. Of the familial cases, about
20% have been linked to gain-of-function mutations in the Cu/Zn
superoxide dismutase (SOD1) gene (Ingre et al., 2015). The most
commonly used animal model for ALS is the high-copy-number
SOD-1 G93A transgenic mouse, which develops hindlimb muscle
wasting and paralysis by 120-130 days old. More than 1000 papers
have been published on this model, many describing successful
prolongation of survival with a range of drugs. Only one of these –
Riluzole – has successfully completed clinical evaluation and on
average only offers a few extra months of survival (Miller et al.,
2012). So why has translation proved so difficult in these studies?
An excellent detailed analysis has been provided by Scott and
colleagues (2008) in which they identified a number of common
flaws in the studies, including inadequate numbers, differences in
males and females (many reports failing to reveal the sex of the mice
used), litter-to-litter variation, failure to censor non-ALS related
deaths, variation in copy number of the transgene, and the use of
inappropriate statistics. They outlined a robust experimental
approach to avoid these problems but, regrettably, relatively few
of the studies published in the last 6 years have conformed to these
guidelines.
How to improve translation to clinical trials
Another problemwith the development of therapies for rare diseases
is the target population. In many rare diseases the natural history of
patients is not well documented or is changing as a result of
improved medical management, which makes it difficult to develop
outcome measures that show the clinical benefit of treatment.
Furthermore, the rarity of the disease often means that clinical trials
need to involve multiple clinical centres and often require
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multinational collaborations. Pharmaceutical and biotechnology
organisations often do not have the in-house expertise in the rare
disease and a good understanding of the reality of clinical trials in
such populations. For novel therapies, the majority of ideas and
initial experiments are performed by academics and clinicians but,
in many cases, these individuals lack experience of how to take
such ideas to clinical trials and the route to drug approval. The
neuromuscular community recognised these issues and, in 2009,
the Treat-NMD international neuromuscular collaboration set up
the Treat-NMD Advisory Committee on Therapeutics (TACT) to
provide advice on drug development for neuromuscular diseases.
Experience from TACT reviews of drug development programmes
has shown the importance of performing high-quality studies in
animal models to underpin drug development proposals (Heslop
et al., 2015).
“For novel therapies, the majority of ideas
and initial experiments are performed by
academics and clinicians but, in many
cases, these individuals lack experience
of how to take such ideas to clinical
trials and the route to drug approval”
It is important to recognise that a statistically significant
improvement in some measure in an animal model might not be
biologically important and sowill lack real translational predictivity.
As a generality, a relatively small change in an animal model is a
poor basis for the development of a therapeutic programme, whereas
large improvements in multiple measures provide more confidence.
The very strong desire to develop treatments for lethal inherited
conditions such as DMD, often coupled with an enthusiasm for a
particular technology or class of drugs, can lead to wishful thinking
and a failure to critically evaluate the results of studies in animal
models of the disease, and this needs to be avoided if we are to see a
greater success rate in translational studies.
“As a generality, a relatively small change
in an animal model is a poor basis for the
development of a therapeutic programme,
whereas large improvements in multiple
measures provide more confidence”
Conclusions
A careful consideration of the drug dose, route of delivery and life
history of the human disease are essential elements in designing
better translational studies in mouse models. An understanding of
the similarities and differences between the mouse model and the
human disease is vital in defining the most appropriate outcome
measures for the animal experiments. The development of standard
operating procedures for such outcome measures allows improved
independent validation of the results. Finally, a critical evaluation of
the treatment effect, rather than just a statistical improvement,
should be used to inform future clinical development. Combining
all of these elements should increase the success rate and minimise
wastage in the development of new treatments for disease.
This article is part of a subject collection on Model Systems in Drug Discovery: from
Bench to Patient. See related articles in this collection at http://dmm.biologists.org/
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